Skip to content
10-Q

Quarterly Report

LIGAND PHARMACEUTICALS INC LGND LGNDZ LGNXZ LGNYZ LGNZZ

0000886163-25-000036

← back to feed
Filed
May 9, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 6, 2025 19.29M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $160.91M
Short Term Investments Q1 2025 · Dec 31, 2024 $183.86M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $47.99M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $72.31M
Current Liabilities Q1 2025 · Mar 31, 2025 $58.68M
Current Liabilities Q1 2025 · Dec 31, 2024 $37.11M
Total Liabilities Q1 2025 · Mar 31, 2025 $109.9M
Total Liabilities Q1 2025 · Dec 31, 2024 $111.34M
Current Assets Q1 2025 · Mar 31, 2025 $309.32M
Current Assets Q1 2025 · Dec 31, 2024 $331.56M
Total Assets Q1 2025 · Mar 31, 2025 $905.44M
Total Assets Q1 2025 · Dec 31, 2024 $941.77M
Shares Diluted Q1 2025 · Mar 31, 2024 18.12M sh
Capex Q1 2025 · Mar 31, 2024 $105K
Operating Cash Flow Q1 2025 · Mar 31, 2024 $18.73M
Stockholders Equity Q1 2025 · Mar 31, 2024 $806.52M
Stockholders Equity Q1 2025 · Dec 31, 2023 $700.91M
Eps Diluted Q1 2025 · Mar 31, 2024 $4.75
Eps Basic Q1 2025 · Mar 31, 2024 $4.86
Sga Expense Q1 2025 · Mar 31, 2024 $10.95M
Rd Expense Q1 2025 · Mar 31, 2024 $5.97M
Net Income Q1 2025 · Mar 31, 2024 $86.14M
Operating Income Q1 2025 · Mar 31, 2024 $2.99M
Revenue Q1 2025 · Mar 31, 2024 $30.98M